4,4-diallyl-5-oxo-pyrrolidine-1,2-(S)-dicarboxylic acid di-tert-butyl ester | 394734-80-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4,4-diallyl-5-oxo-pyrrolidine-1,2-(S)-dicarboxylic acid di-tert-butyl ester
• 英文别名: di-tert-butyl (2S)-4,4-diallyl-5-oxo-pyrrolidine-1,2-dicarboxylate；Di-tert-butyl (S)-4,4-diallyl-5-oxopyrrolidine-1,2-dicarboxylate；ditert-butyl (2S)-5-oxo-4,4-bis(prop-2-enyl)pyrrolidine-1,2-dicarboxylate
• CAS: 394734-80-6
• 化学式: C₂₀H₃₁NO₅
• 分子量: 365.47
• InChiKey: PVVWGNMZPRRUQV-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4,4-diallyl-5-oxo-pyrrolidine-1,2-(S)-dicarboxylic acid di-tert-butyl ester 在 三乙基硼氢化锂 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 4,4-diallylpyrrolidine-1,2-(S)-dicarboxylic acid di-tert-butyl ester
  参考文献：
  名称：

  [EN] MASP INHIBITORY COMPOUNDS AND USES THEREOF
  [FR] COMPOSÉS INHIBITEURS DE MASP ET LEURS UTILISATIONS

  摘要：

  本发明涉及新型甘霖结合凝集素（MBL）相关丝氨酸蛋白酶（MASP）抑制化合物，以及其类似物和衍生物，以及其制备方法，单独或组合用于治疗和/或预防疾病，以及用于生产药物治疗和/或预防疾病，特别是用于治疗和/或预防肾脏和心血管疾病以及缺血再灌注损伤。

  公开号：

  WO2020225095A1
• 作为产物：
  描述：

  (S)-N-叔丁氧羰基-2-吡咯烷酮-5-甲酸叔丁酯 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 生成 4,4-diallyl-5-oxo-pyrrolidine-1,2-(S)-dicarboxylic acid di-tert-butyl ester
  参考文献：
  名称：

  Discovery of SCH446211 (SCH6):  A New Ketoamide Inhibitor of the HCV NS3 Serine Protease and HCV Subgenomic RNA Replication

  摘要：

  Introduction of various modified prolines at P-2 and optimization of the P-1 side chain led to the discovery of SCH6 (24, Table 2), a potent ketoamide inhibitor of the HCV NS3 serine protease. In addition to excellent enzyme potency (K-i* = 3.8 nM), 24 was also found to be a potent inhibitor of HCV subgenomic RNA replication with IC50 and IC90 of 40 and 100 nM, respectively. Recently, antiviral activity of 24 was demonstrated with inhibition of the full-length genotype 2a HCV genome. In addition, 24 was found to restore the responsiveness of the interferon regulatory factor 3 (IRF-3) in cells containing HCV RNA replicons.

  DOI：

  10.1021/jm060077j

文献信息

• Design and Synthesis of Building Blocks for PPII-Helix Secondary-Structure Mimetics: A Stereoselective Entry to 4-Substituted 5-Vinylprolines
  作者：Slim Chiha、Arne Soicke、Matthias Barone、Matthias Müller、Judith Bruns、Robert Opitz、Jörg-Martin Neudörfl、Ronald Kühne、Hans-Günther Schmalz

  DOI：10.1002/ejoc.201701584

  日期：2018.1.31

  Starting from pyroglutamic acid, 4‐substituted‐5‐vinylprolines were stereoselectively prepared and used as building blocks for the synthesis of conformationally well‐defined diproline analogs, which are of interest as proline‐derived modules (ProMs) for the construction of PPII‐helix secondary‐structure mimetics acting as inhibitors of relevant protein‐protein interactions.

  从焦谷氨酸开始，立体选择性地制备了4-取代的5-乙烯基脯氨酸，并将其用作合成构象明确的二脯氨酸类似物的基础，这是脯氨酸衍生的模块（ProMs），可用于构建PPII-螺旋二级结构模拟物可作为相关蛋白质相互作用的抑制剂。
• [EN] MASP INHIBITORY COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS INHIBITEURS DE MASP ET LEURS UTILISATIONS
  申请人：BAYER AG

  公开号：WO2020225095A1

  公开（公告）日：2020-11-12

  The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.

  本发明涉及新型甘霖结合凝集素（MBL）相关丝氨酸蛋白酶（MASP）抑制化合物，以及其类似物和衍生物，以及其制备方法，单独或组合用于治疗和/或预防疾病，以及用于生产药物治疗和/或预防疾病，特别是用于治疗和/或预防肾脏和心血管疾病以及缺血再灌注损伤。
• NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS
  申请人：Saksena Anil K.

  公开号：US20110117057A1

  公开（公告）日：2011-05-19

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

  本发明披露了具有HCV蛋白酶抑制活性的新化合物，以及制备这些化合物的方法。在另一种实施方式中，本发明披露了包含这些化合物的制药组合物，以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
• MASP INHIBITORY COMPOUNDS AND USES THEREOF
  申请人：Bayer Aktiengesellschaft

  公开号：US20210246166A1

  公开（公告）日：2021-08-12

  The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.
• USRE43298E1
  申请人：——

  公开号：USRE43298E1

  公开（公告）日：2012-04-03